Publications

2018

• Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.
  Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T, Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO)
  Leukemia 2018, 32(9), 2085-7
  
• Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how.
  Heidel FH, Ellis S
  Oncotarget 2018, 9(78), 34642-3
  
• Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018.
  Heidel FH, Gale RP, Hochhaus A
  Leukemia 2018, 32(5), 1055-6
  
• Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging.
  Kosan C, Heidel FH, Godmann M, Bierhoff H
  Cells 2018, 7(12)
  
• Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
  Marhäll A, Heidel F, Fischer T, Rönnstrand L
  Ann Hematol 2018, 97(5), 773-80
  
• The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
  Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH
  Leukemia 2018, 32(5), 1211-21
  
• Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
  Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R
  Br J Haematol 2018, 183(1), 35-46
  
• Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.
  Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G
  Leuk Res 2018, 74, 86-8
  
• Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large mu
  Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N
  Semin Hematol 2018, 55(4), 248-55
  
• Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
  Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M
  Hematol Oncol 2018, 36(1), 285-90